Additionally, enhancing SERCA2 functionality can improve pancreatic β-cell performance [9,15], support the development of beige adipose tissue, and increase energy expenditure [16], highlighting its potential as a therapeutic target for treating NAFLD. This evidence concerns the gene ATP2A2 and metabolic dysfunction-associated steatotic liver disease.